YKYY017 for COVID-19: real-time analysis

Download Image

Post

c19early.org

YKYY017 for COVID-19

1 study with 239 patients

Serious outcome risk

YKYY017

Control

Significantly lower risk for recovery.

COVID-19 YKYY017 studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−150%

Viral clearance (1)13%

RCTs (1)−150%

Early (1)−150%

00.511.5+

← YKYY017
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Aug 7 2025	Wang et al., Nature Communication, doi:0.1038/s41467-025-62214-x	The efficacy and safety of inhaled peptide YKYY017 for COVID-19 patients with mild illness: a phase 2 randomized controlled trial
Aug 7 2025	31% improved recovery (p=0.003) and 13% improved viral load (p=0.08). RCT 239 mostly mild COVID-19 outpatients showing the primary endpoint of viral load reduction at day 4 was not met with inhaled peptide YKYY017. The 20mg group showed significantly faster time to recovery. The study population was low-ris..